Industry Reports

GS 3Q21: Another Blowout Quarter, Is it on Steroids or HGH?


GS did it again as it retains its HR derby results in the big/bank sector. Economic earnings exceed Citigroup's and breathing down BAC's back. But how sustainable are these grand-slam quarters. We investigate and judge the "Aaron Judge" performer of the big bank pack. 

U.S. Regional Banks: Next Moves & Reviews


Regional banks had a good 1Q21, but mostly on non-core reserve releases. We review the fee income revenues line by showing the winners and losers and how the major ones can resume growth with a normailzing economy. Spreads are largely too tight as technicals overide credit concerns. 

Big Banks ALM 2020: Crushed on NII, Noninterest Income Hedge


Big banks 2020 10Ks are out and we conduct our annual ALM reviews. Rates got crushed in net interest income as asset yields fell faster than liabilities. Asset volumes could not make up for the deficit though noninterest income hedged it better for some big banks like JPMorgan. 

Pandemic Hits Parade Part II: Higher Losses, But More Buybacks


CCAR II gets banks back into the stock buyback game even with higher losses. But some may be delayed due to their regulatory consent orders like WFC and Citi. Credit cards hit big banks more. CRE hits regionals more. More a driver of stock prices than the rest of the capital structure, although perpetual preferreds should rally more. 

Big Banks @ GS: Hoping Reserves are Fine as Vaccines Roll Out


Big banks rounded out the annual GS Financials conference, and all are looking ahead to happy days as the vaccines roll-out in 2021. BAC sees more consumer spending, Citi getting ready for new CEO and consent order implementation, and JPMorgan looks for asset management expansion deals. 

U.S. Regionals @ GS: To Buy or Not to Buy, That is the Question? Selling Ainít Too Good Either!


U.S. regional banks look forward to vaccines, but hate the sight of low rates. Foraging for fee income is the way to survive with some better positioned than others. 

Risk Mgt Chat: The End of LIBOR: SOFR & Compounding Calculations


Recent risk management panel focuses on the operational risks and more complex SOFR compounding calculations as LIBOR transitions away in 2021.  

Risk Mgt Chat: LIBOR Lunacy: Whoís on First, Whatís on Second, I Donít Know is on for 2021!?!


LIBOR deliberations &discussions have been as coherent as a pub imbibed dissertation on alternative views as to the start of the universe. In other words, another Federal Reserve bobbling of the goals and aspirations for a more equitable benchmark rate market. And wasn't that supposed to be the improvement after the LIBOR scandals. Yikes again. Thanks Fed!

Viola Risk on Equity Derivatives: Hot Driver in Big Tech Stock/Options Rally & Meltdown


Equity markets and related options for single stocks and indices have been rocked by the Big Tech stock/options squeeze undertaken by Softbank. There will be big negative impacts to providers of equity derivative protection as the big banks and brokers in the US and Europe get snagged in the Softbank stock snafu. ​

Webinar: New Constructs & Viola Risk Advisors: Why the Tech Carnage Can Continue!


A new generation of investors are learning the equity valuation lessons the hard way as unrealistic and way too high equity valuations are coming crashing down in the Big Tech stock/options world. And there is spillover effects to Big Banks equity/debt & counterparty/regulatory risk as these banks provided the volatility chum that the Japanese Whale craved. Please join us for this excellent capital structure webcast jointly presented by New Constructs (our equity valuation specialist) and Viola Risk Advisors. 

Page: 1 2 3 4 5 6 7 8 9 10